Will Exopharm (ASX:EX1) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Australian (ASX) Biotech Industry Analysis
UpdatedMay 28, 2022
DataAggregated Company Financials
Companies37
- 7D-2.2%
- 3M1.9%
- 1Y-9.9%
- YTD-11.8%
Over the last 7 days, the Biotech industry has dropped 2.2%, driven by a pullback from CSL of 2.2%. Meanwhile, Aroa Biosurgery actually outperformed within the industry, gaining 5.8% in the last week. Overall the industry is down 9.9% in 12 months. As for the next few years, earnings are expected to grow by 16% per annum.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sat, 28 May 2022 | AU$136.2b | AU$15.3b | AU$2.7b | 35.5x |
| Mon, 25 Apr 2022 | AU$137.7b | AU$14.8b | AU$2.7b | 38x |
| Wed, 23 Mar 2022 | AU$135.6b | AU$14.5b | AU$2.6b | 40x |
| Fri, 18 Feb 2022 | AU$143.0b | AU$15.0b | AU$2.7b | 41.2x |
| Sun, 16 Jan 2022 | AU$143.5b | AU$14.5b | AU$2.8b | 40.2x |
| Tue, 14 Dec 2021 | AU$148.0b | AU$14.6b | AU$2.8b | 40.9x |
| Thu, 11 Nov 2021 | AU$156.4b | AU$14.2b | AU$2.7b | 44.4x |
| Sat, 09 Oct 2021 | AU$144.5b | AU$14.3b | AU$2.7b | 40.8x |
| Mon, 06 Sep 2021 | AU$151.7b | AU$14.0b | AU$2.6b | 44x |
| Wed, 04 Aug 2021 | AU$143.8b | AU$14.0b | AU$2.6b | 42x |
| Sat, 08 May 2021 | AU$132.5b | AU$13.5b | AU$2.8b | 37.3x |
| Tue, 09 Feb 2021 | AU$132.3b | AU$13.1b | AU$3.0b | 35.8x |
| Mon, 02 Nov 2020 | AU$138.5b | AU$13.5b | AU$2.9b | 31.2x |
| Thu, 06 Aug 2020 | AU$130.3b | AU$13.5b | AU$2.7b | 40.3x |
| Sun, 10 May 2020 | AU$146.8b | AU$14.9b | AU$3.0b | 42x |
| Sat, 01 Feb 2020 | AU$149.3b | AU$12.9b | AU$2.5b | 49.6x |
| Tue, 05 Nov 2019 | AU$122.7b | AU$13.1b | AU$2.6b | 65.6x |
| Fri, 09 Aug 2019 | AU$109.0b | AU$12.3b | AU$2.4b | 62.9x |
Median PE Ratio
67.4x
Current Industry PEThere are only 2 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have grown 6.3% per year over the last three years.
- Revenues for these companies have grown 8.4% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Australian Biotech compare with similar industries?
| AU Market | -1.30% | |
| Healthcare | -1.59% | |
| Biotech | -2.20% | |
| Biotech | -2.20% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ARX Aroa Biosurgery | AU$0.82 | 5.8% +AU$15.4m | -32.0% | PS7.8x | |
| PAR Paradigm Biopharmaceuticals | AU$1.21 | 3.0% +AU$8.0m | -46.9% | PS4303.6x | |
| PTX Prescient Therapeutics | AU$0.17 | 6.5% +AU$6.5m | 50.0% | PS78.2x | |
| CYP Cynata Therapeutics | AU$0.40 | 12.7% +AU$6.4m | -32.2% | PS6.8x | |
| PYC PYC Therapeutics | AU$0.073 | 2.8% +AU$6.4m | -54.4% | PS25.6x |